

AMENDMENTS TO THE CLAIMS

1. (Canceled)

2. (Currently amended) A method of treating an inflammatory disease or condition in a mammal, comprising ~~selecting an LXR agonist that exhibits a greater effect on expression of an inflammatory gene than on expression of a lipid metabolism gene, and administering to the mammal an amount of said~~ an LXR agonist sufficient to treat the disease or condition, such that inflammation is reduced without a significant effect on lipid metabolism, wherein said LXR agonist is GW3965 or T0901317.

3. (Canceled)

4. (Canceled)

5. (Previously presented) The method of Claim 2, wherein the inflammatory disease or condition is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, degenerative joint disease, one or more connective tissue diseases, ankylosing spondylitis, bursitis, Sjogren's syndrome, psoriasis, psoriatic arthritis, neuralgia, synovitis, glomerulonephritis, vasculitis, sarcoidosis, atherosclerosis, asthma, inflammatory bowel disease, inflammations that occur as sequelae to influenza, the common cold and other viral infections, gout, contact dermatitis, low back and neck pain, dysmenorrhea, headache, toothache, sprains, strains, myositis, burns, injuries, and pain and inflammation that follow surgical and dental procedures in a patient.

6.-13. (Canceled)

14. (Previously presented) The method of claim 2, wherein said inflammatory disease or condition is macrophage-dependent.

15. (Previously presented) The method of Claim 14, wherein said inflammatory disease or condition is atherosclerosis, rheumatoid arthritis, or glomerulonephritis.

16.-20. (Canceled)